Health & Biotech
Beyond resources: WA aims to be medical and life sciences powerhouse
Check Up: Aussie biotech Ternarx to pioneer next-gen cancer medicine, and recent ASX health winners
ASX Health Stocks: Immutep gets crucial therapy trial clearance; Alcidion wins $4m deal
Weed Week: Getting a grip on the cannabis scene amid a pending regulatory shakeup
Vital Signs Podcast: Optiscan
PharmAust’s monepantel drug hits strategic milestone with selection for prestigious ALS treatment trial
National biotech summit shows off a wealth of healthcare and medical innovation
Althea launches new dried medicinal cannabis flower range
Investors’ sneak peek at biotech’s bright future
Orthocell to sell Striate+ in Canada after regulatory approval
Neurotech reports further positive Phase 2/3 autism trial results
Investors are all ears as Orthocell’s nerve and tissue solutions deliver record revenue
Neurotech chasing prized US orphan drug designation
EZZ launches EAORON products in Vietnam
Dr Boreham’s Crucible: Is this dendrimer believer on the verge of a corporate renaissance?
Lumos steps up antibiotic resistance fight to Australia & NZ
ScoPo’s Powerplays: ASX health stocks hit resistance in first week of FY25
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.